Aldeyra Therapeutics, Inc. · NASDAQ:ALDX

Aldeyra Therapeutics — Technical Presentation (March 2020)

7 slides from Aldeyra Therapeutics's technical presentation, Mar 24, 2020

  1. Slide 1: The Novel Aldehyde Trap, ADX-102, Reduces Inflammation-Mediated Lung Infiltrate in a Mouse Model

    PP-167 The Novel Aldehyde Trap, ADX-102, Reduces Inflammation-Mediated Lung Infiltrate in a Mouse Model of LPS-Induced Acute Lung Injury Susan G. Macdonald 1, Valerie Cullen 2, Todd Brady1, Dominic Beal 3, Paulette W. Andreotta3, Scott L. Young 4 Objective This study was conducted to evaluate the ac

  2. Slide 2: Results

    Results LPS challenge perturbed the pressure-volume relationship in the lung, showing a shift down and to the right, indicating decreased volume associated with increased pressure, as compared to the saline control group, which is indicative of increased lung stiffness. LPS challenge also led to inc

  3. Slide 3: * p < 0.05; *** p < 0.001; ****p < 0.0001

    * p < 0.05; *** p < 0.001; ****p < 0.0001 01; *** p < 0.001

  4. Slide 4: Lung mechanics and cytokine results with ADX-102

    < 0.001 In lung mechanics tests, LPS-challenged mice treated with ADX-102 showed a curve shift up and to the left relative to the vehicle, indicating substantially reduced lung stiffness and improved lung compliance and elastance, although these measures were not statistically significant (Figure 4)

  5. Slide 5: p < 0.0001 p g /m L IL 1 2 p 7 0

    p g /m L p g /m L p g /m L 0 20 40 60 80 0 20 40 60 0 50 100 150 200 250 S S S a a a li li li n n n e e e V V V *** e *** e e **** h h h ic ic ic le le le A A A D D D X X X L IF -1 -1 -1 0 IF N g D 0 D 0 D 2 2 2 e e e x * IP IL 1 2 p 4 0 x IP x IP a * ** a a m m m e e e th th th a a a s s s o o o n

  6. Slide 6: Discussion

    Figure 6 Discussion Treatment of LPS-challenged animals with ADX-102 statistically significantly reduced LPS-induced increases in total cells, macrophages, lymphocytes and eosinophils in BALF. Although neutrophils were also reduced, statistical significance was not reached in that cell population, p

  7. Slide 7: Conclusions

    via a novel anti-inflammatory mechanism that could involve reduced vascular permeability in lung and/or diminished chemotaxis. Conclusions The data show that ADX-102 can significantly reduce inflammation in LPS-induced lung injury via a mechanism that differs from corticosteroids, and build on exist

Aldeyra Therapeutics — Technical Presentation (March 2020) on 6ix